Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.

BACKGROUND: The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. MATERIALS AND METHODS: The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population. RESULTS: In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population. CONCLUSIONS: Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.

Prevalence of comorbidities in periodontitis patients compared with the general Austrian population.

BACKGROUND: The majority of patients with periodontitis present with comorbidities, however only little is known on prevalence of these comorbidities in comparison with the general population. This study aims to analyze the prevalence and impact of comorbidities in patients with periodontitis in Austria. METHODS: Prevalence of comorbidities was evaluated in 1,199 patients with periodontitis (median age: 49, range: 14 to 83 years). These data were compared with a randomly selected age- and sex-matched cohort of the Austrian population by an unconditional logistic regression model. RESULTS: Comorbidities were found in 821 of 1,199 (68.5%) patients. Allergies had the highest prevalence (29.2%), followed by hypertension (19.4%), musculoskeletal (11.2%), and endocrine disorders (9.7%). Chronic pulmonary disorders (no influenza/pneumonia) were associated with a higher approximal plaque index (72% versus 63%, P = 0.02). No association between characteristics of periodontitis and comorbidities was observed. Prevalence of allergies (29.2% versus 22.9%) and pulmonary disorders (8.5% versus 4.3%) was significantly higher in periodontitis patients compared with the Austrian population (P < 0.001), whereas asthma (1.5% versus 5.6%), cardiovascular disorders (1.8% versus 10.5%), depression (7.1% versus 10.4%), headache (1.3% versus 20%), hyperlipidemia (6.4% versus 14.8%), hypertension (14.2% versus 24.5%), musculoskeletal disorders (11.2% versus 41.7%), and osteoporosis (2.8% versus 5.1%) were found less frequently (P < 0.001). No differences were observed for cancer, diabetes mellitus, gastrointestinal disorders, or psychiatric disorders (P = 0.95, P = 0.76, P = 0.68, P = 0.23, respectively). CONCLUSION: In Austria, the majority of patients with periodontitis present with comorbidities, and the adjusted prevalence differs significantly from the general population.